Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.47 |
| ▸ | PDE4A | P27815 | 3/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28348174 | 1.00 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL21768003 | 1.00 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL8096846 | 0.80 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7828978 | 0.80 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8096843 | 0.80 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21767998 | 0.76 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL21767999 | 0.76 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL21768004 | 0.73 | NR3C1 (0.41) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL30477925 | 0.73 | NR3C1 (0.41) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL21780949 | 0.71 | MAPT (0.47) | TP53SMN1; SMN2GAAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389411-B2 | Pharmaceutical composition, containing NM23 activator, for inhibiting cancer metastasis | EWHA University—Industry Collaboration Foundation (KR) | 2022-07-19 | — | — | US | disclosed |
| US-20200078319-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2020-03-12 | — | — | US | disclosed |
| EP-3616692-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | Ewha University-Industry Collaboration Foundation (KR) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078319-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | NME1, NTPCR, NME2 | PDE4B 1938/4885PDE4A 1705/4885PDE4C 1862/4885 |
| US-11389411-B2 | Pharmaceutical composition, containing NM23 activator, for inhibiting cancer metastasis | NME1, NTPCR, NME2 | PDE4B 1938/4885PDE4A 1705/4885PDE4C 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.